Plasma exchange's '2.6 years younger' headline was a gap against the placebo group — not a change in anyone's clock, a transfusion specialist warns
Edited by Samael A. Tejada, Founder & Editor-in-Chief
·Tip: press play, then lock your phone or switch apps — the article keeps reading.
The widely quoted claim that plasma exchange made people '2.61 years younger' comes from a small Aging Cell pilot (about 10 people per arm) in which that figure was a mid-treatment difference versus the sham group — no group's biological clock changed significantly from its own baseline, and the gap was gone by the final check (critique by Dr. Caitlin Raymond, Hemostasis Today, November 4, 2026). No clinical or mitochondrial outcome was measured.
The press release said plasma exchange turned back biological age by 2.6 years. The paper itself — read slowly, the way a physician who runs these machines for a living just read it — says something narrower, weaker and much more interesting: a gap that opened mid-treatment and closed by the end.
What did the trial actually do?
Fuentealba and colleagues randomized — in their own abstract's words, 'based on entry date' — 44 healthy adults over 50 into four arms of about 10 to 11 people: biweekly plasma exchange with IVIG, biweekly plasma exchange alone, monthly plasma exchange, and a sham procedure (the apheresis machine run against a container of water, a genuinely strong control). One plasma volume was exchanged per session with 5% albumin replacement. Blood drawn before sessions 1, 4 and 6 was profiled across dozens of biological-age clocks and multi-omics panels. Safety was acceptable for a pilot: one mild allergic reaction across 240 procedures, per the corrected text, with the abstract reporting two adverse events requiring discontinuation, one IVIG-related.
Where does 2.61 years come from — and where did it go?
At the middle timepoint — blood drawn before session 4, after just three sessions — the biweekly TPE-plus-IVIG arm's average clock reading sat 2.61 years below the sham arm's. The monthly arm sat 1.32 years below sham at the same timepoint (a figure some coverage mislabels as 'TPE alone'). But a difference from a drifting, 10-person comparator is not a change in the treated: with correction for the 36 clocks tested, no arm's clock changed significantly from its own baseline at either follow-up, and most clocks already differed between groups at baseline. By the final timepoint, after five sessions, no group differed significantly from sham in any arm. In Raymond's words, the vanishing signal 'is the most interesting result in the manuscript, and it is not in the abstract.' The paper is also candid that there were 'no clinically meaningful changes (e.g., functional, cognitive, or symptomatic) observed or assessed.'
What is the mitochondria angle — and the conflict to know?
Plasma exchange is marketed in the longevity world with cellular-rejuvenation language that often name-checks mitochondrial renewal. This trial measured no mitochondrial outcome at all: the protein signals that tracked with response were enriched for chronic inflammation, cellular senescence and loss of proteostasis, and 'mitochondrial dysfunction' appears only as one hallmark category label in the methods. Readers pricing an expensive TPE series should also know the paper's conflict statement: senior figures include the co-founder and chief scientific officer of Circulate, the company selling this protocol, alongside Buck Institute investigators — even though the funding line reads 'no specific funding.' Raymond's verdict is measured: 'a good pilot' — whose oversell happened 'upstream, in the abstract and the press release, because the abstract is the part everyone quotes.'
Frequently asked questions
Did plasma exchange make participants 2.61 years younger?
No — not in the way the headline implies. 2.61 years was the mid-treatment difference between the biweekly TPE-plus-IVIG group's average clock reading and the sham group's. No group's clock changed significantly from its own baseline, and by the final timepoint no group differed significantly from sham.
How big was the plasma exchange trial?
Forty-four healthy adults over 50 enrolled and 42 completed, across four arms of roughly 10 people each, over three to six sessions. Assignment was based largely on entry date, and baseline clock readings already differed between groups.
Did the trial measure mitochondrial function?
No. Despite cellular-rejuvenation marketing around plasma exchange, the trial reported no mitochondrial outcome; its response signals were enriched for inflammation, senescence and proteostasis hallmarks instead.
Where the evidence stands
- Established: The arithmetic of the critique is checkable in the paper itself: between-arm mid-treatment differences, no significant within-group change from baseline after correction, and no between-group difference at the final timepoint.
- Contested: Whether TPE produces any real biological-age effect at all. The pilot's own corrected statistics do not show one; proponents point to nominal trends. Only a larger, properly randomized trial with clinical endpoints could settle it.
- Absent: Clinical outcomes (function, cognition, symptoms) and any mitochondrial outcome — neither was measured.
Join the discussion
To get the conversation started: What questions does this story raise for you? Share them below — every comment is reviewed by our moderators before it appears.
Community discussion only — not medical advice. Every comment is reviewed by our moderators before it appears. Sign in with Google or a free Hyvor account to join in.